Q-omics provides the consensus-scored TMEM235 profile across patient tissues and cancer cell-line models. TMEM235 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM235 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, TMEM235 RNA expression shows 13,472 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TMEM235 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM235 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM235 survival associations across molecular data types. TMEM235 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM235 RNA expression–survival associations across cancer types. High TMEM235 expression shows unfavorable associations in KIRC, KICH, COAD, UCEC and OV, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM235 RNA expression.
This table summarizes TMEM235 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM235. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM235 shows lower tumor expression in THCA and LIHC and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher TMEM235 RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p = .001).
This table shows molecular features associated with TMEM235 in patient tissues and cancer cell lines. In patient samples, TMEM235 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM235 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
